The members of the biomea team are all seasoned biotech executives who have successfully developed multiple drugs from the early preclinical design work and testing up to and through the clinical development phase and into commerciality.
Founder & Chief Executive Officer
Prior to forming biomea, Tom managed Investor Relations at Pharmacyclics Inc., where he helped grow the company from a market cap of $6.74B to over $21B, which included the execution of one of the largest biotech acquisitions to date. Prior to Pharmacyclics, Inc., Tom spent 6 years as a medicinal chemist at Gilead Sciences Inc. engaging in novel drug design and drug development of HCV polymerase and protease inhibitors. Tom holds an M.B.A. from the University of California Los Angeles (2012) and a Master's degree in Organic Chemistry from the University of California Santa Barbara (2007). As a research scientist, Thomas Butler has been awarded numerous patents in the U.S. and internationally, as well as published in top academic journals such as the American Chemical Society Journal of Medicinal Chemistry and Angewandte Chemie. Tom currently also serves a Managing Partner at Point Sur Investors, where he oversees - together with Ramses - a biotech long-only fund investing in innovative therapies that significantly improve the standard of care.
Founder & President
Ramses most recently served as the Executive Vice President of Corporate Affairs for Pharmacyclics, Inc. At Pharmacyclics, he helped grow the company from approximately 40 employees with a market cap of $40M in 2009 to 650 employees and a market cap of $21B in 2015, when it merged with AbbVie, Inc. Ramses was involved in the operational expansion of the company and oversaw various departments during the growth phase including Finance, HR, Legal, Communications, IR, Facilities, Events, and IT. Prior to joining Pharmacyclics, Inc., Ramses managed assets for US high net-worth equity investors and large European closed-end funds. Ramses began his career at Commerzbank AG in Germany, where he was an investment banker and portfolio manager for international clients. He earned the Diplom Kaufmann degree with distinction in Finance and Banking from the Westfaelische Wilhelms Universität of Muenster, Germany.
Eric Schoenmakers, Ph.D.
Head of Preclinical Development & Analytical Sciences
Eric most recently worked as an independent consultant providing services across his wide spectrum of expertise, including Preclinical R&D, Translational Medicine, Biomarker and CDx Development, and GxP/Quality Management. Before that he served as a Director Clinical Genetics within the Translational Medicine team at Pharmacyclics, Inc. Prior to joining Pharmacyclics, Eric headed the Pfizer Oncology Clinical Research Laboratory at Pfizer’s Global R&D site in La Jolla, CA. Eric started his career in academia, and was a tenured faculty member at the Department of Human Genetics in Nijmegen, The Netherlands for over a decade. He earned a MSc. in Biology (with majors in Molecular Biology, Genetics, and Immunology) at the University of Nijmegen, The Netherlands, and a summa cum laude doctorate in Human (Cancer) Genetics from the University of Leuven, Belgium. He has been awarded several US and international patents in the field of tumorigenesis and diagnostics, co-authored over a hundred peer-reviewed publications in top-tier international journals including Nature Genetics and the Journal of Clinical Oncology, and has been a scientific grant reviewer for over a dozen scientific organizations worldwide.
Member of the Science Team:
James is a consultant to the biotechnology and pharmaceutical industry, working in drug discovery programs targeting oncology, cardiovascular, and infectious diseases. His responsibilities include structure-based drug design and guidance of contract research teams whose tasks include chemistry, bioassays, pharmacology, and GMP manufacturing. Formerly, Jim was employed by Biota Pharmaceuticals, Melbourne, Australia as Director, Drug Discovery, responsible for coordinating Biota’s antibacterial research discovery program. Prior to this he was Head of Chemistry at Cytopia, Melbourne, from 2007-2009. Before joining Cytopia, Jim was Senior Director, Medicinal Chemistry, at Celera Genomics, where he led the team that discovered Imbruvica® (ibrutinib), now approved for CLL and other indications. Jim’s teams have contributed to the discovery and development of several other clinical and late stage preclinical candidates, including odanacatib (Phase III, Merck, osteoporosis), momelotinib (Phase III, Gilead, myelofibrosis), abexinostat (Phase II, Pharmacyclics, oncology), and K11777 (UCSF/OneWorld Health, Chagas disease). He undertook post-doctoral studies at Purdue University, having obtained a Bachelor of Science in Chemistry (1979, Old Dominion University) and a Ph.D. in Organic Chemistry (1985, Purdue University), and has co-authored over 60 peer-reviewed publications and conference presentations, and is an inventor on over three dozen issued patents and published applications.